Skip to content
Screener

Relay Therapeutics, Inc. RLAY Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue-
EPS-$0.43Miss by $0.04
EPS estimate-$0.39

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.6M
EPS estimate-$0.40

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$80.4M+16.6%
Net income-$74.1M+15.8%
EPS (diluted)-$0.43+31.7%

Balance sheet

See full
Cash & equivalents$91.6M-39.9%
Total debt$33.3M-33.1%
Total equity$607.7M-27.6%
Total assets$670.0M-28.0%

Cash flow

See full
Operating cash flow-$62.1M+17.3%
CapEx--100%
Free cash flow-$62.1M+17.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$899.99M-4.3%
Enterprise value$841.75M+0.5%
P/S107.7×+13.7×

Profitability

See full
Operating margin-3,914.4%+128pp
Net margin-3,561.4%+119pp
FCF margin-2,978.3%+173pp

Returns & leverage

See full
Return on equity-41.1%-1.4pp
Debt / equity0.1×0.0×
Current ratio19.1×+0.7×

FAQ

When did Relay Therapeutics, Inc. report Q3 2025 earnings?
Relay Therapeutics, Inc. (RLAY) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Relay Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Relay Therapeutics, Inc. reported revenue of - and eps of $-0.43 for Q3 2025.
Did Relay Therapeutics, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.39 by $0.04.
How did Relay Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 31.7% from $-0.63.
Where can I find Relay Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269536) and the 10-Q periodic report (0001193125-25-269601) directly on SEC EDGAR. The filing index links above go to sec.gov.